We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current RNA market cap is 3.8B. The company's latest EPS is USD -1.7787 and P/E is -17.89.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.82M | 2.19M | 3.54M | 2.05M | 2.34M |
| Operating Income | -58.63M | -66.74M | -77.19M | -82.63M | -98.13M |
| Net Income | -52.36M | -60.44M | -68.86M | -70.79M | -80.4M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.32M | 6.79M | 9.33M | 9.22M | 9.56M |
| Operating Income | -17.33M | -44.28M | -118.05M | -178.91M | -235.6M |
| Net Income | -24.73M | -44.36M | -118.01M | -174M | -212.22M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 573.16M | 628.56M | 951.47M | 1.35B | 1.64B |
| Total Liabilities | 55.7M | 127.79M | 120.58M | 126.39M | 137.39M |
| Total Equity | 517.47M | 500.76M | 830.9M | 1.22B | 1.5B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 96.91M | 333.9M | 427.58M | 638.8M | 628.56M |
| Total Liabilities | 27.54M | 27.68M | 46.15M | 60.73M | 127.79M |
| Total Equity | -65.36M | 306.22M | 381.43M | 578.08M | 500.76M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -135.57M | -119.06M | -70.38M | -135.38M | -201M |
| Investing | -181.11M | -130.07M | -32.75M | -307.62M | -790.03M |
| Financing | 61.97M | 93.86M | 389.45M | 836.17M | 1.18B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 2.49M | -37.12M | -94.81M | -136.27M | -119.06M |
| Investing | -235k | -7.79M | -82.52M | -189.96M | -130.07M |
| Financing | 89.23M | 272.04M | 176.32M | 346.17M | 93.86M |
| Market Cap | 3.8B |
| Price to Earnings Ratio | -17.89 |
| Price to Sales Ratio | 397.25 |
| Price to Cash Ratio | 20.51 |
| Price to Book Ratio | 7.58 |
| Dividend Yield | - |
| Shares Outstanding | 119.31M |
| Average Volume (1 week) | 1.66M |
| Average Volume (1 Month) | 1.26M |
| 52 Week Change | 251.21% |
| 52 Week High | 56.00 |
| 52 Week Low | 8.37 |
| Spread (Intraday) | 17 (36.17%) |
| Company Name | Avidity Biosciences Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.aviditybiosciences.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
